AR125461A1 - Células presentadoras de antígeno recombinante - Google Patents

Células presentadoras de antígeno recombinante

Info

Publication number
AR125461A1
AR125461A1 ARP220101095A ARP220101095A AR125461A1 AR 125461 A1 AR125461 A1 AR 125461A1 AR P220101095 A ARP220101095 A AR P220101095A AR P220101095 A ARP220101095 A AR P220101095A AR 125461 A1 AR125461 A1 AR 125461A1
Authority
AR
Argentina
Prior art keywords
recombinant antigen
nucleic acid
acid molecules
antigen presenting
presenting cells
Prior art date
Application number
ARP220101095A
Other languages
English (en)
Inventor
Nandhu Sobhana
Alisha Bothun
Gil Benezer
Shruti Badkar
Rabi Mishra
Hui Chang
- Li Wanwen Hsin
Mansi Soni
Lin Cao
Xi Shi
Mengyao Luo
Manoj Gupta
Akito Nakamura
Doanh Mai
Rosa Ng
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR125461A1 publication Critical patent/AR125461A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)

Abstract

La presente descripción proporciona células presentadoras de antígenos recombinantes y métodos de uso de las mismas en el cultivo y expansión de células inmunitarias ex vivo. En algunos aspectos, las células inmunitarias expandidas a través del cocultivo de las células presentadoras de antígenos recombinantes descriptas en la presente se administran a un sujeto para tratar una enfermedad o afección en el sujeto, por ejemplo, para tratar un cáncer. Reivindicación 1: Una célula presentadora de antígeno recombinante (RAPC), que comprende (i) una o más moléculas de ácido nucleico que codifican IL-21 y (ii) una o más moléculas de ácido nucleico que codifican OX40L. Reivindicación 2: La RAPC de la reivindicación 1, que además comprende (iii) una o más moléculas de ácido nucleico que codifican 4-1BBL. Reivindicación 3: La RAPC de la reivindicación 1 o 2, que además comprende (iv) una o más moléculas de ácido nucleico que codifican IL-15.
ARP220101095A 2021-04-27 2022-04-27 Células presentadoras de antígeno recombinante AR125461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163180530P 2021-04-27 2021-04-27

Publications (1)

Publication Number Publication Date
AR125461A1 true AR125461A1 (es) 2023-07-19

Family

ID=81597826

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101095A AR125461A1 (es) 2021-04-27 2022-04-27 Células presentadoras de antígeno recombinante

Country Status (5)

Country Link
EP (1) EP4330377A2 (es)
CN (1) CN117203328A (es)
AR (1) AR125461A1 (es)
TW (1) TW202309269A (es)
WO (1) WO2022229884A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147404A2 (en) * 2022-01-26 2023-08-03 Rutgers, The State University Of New Jersey Compositions and methods for expanding immune cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
SG10201510092QA (en) 2010-12-09 2016-01-28 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG192010A1 (en) 2011-01-18 2013-08-30 Univ Pennsylvania Compositions and methods for treating cancer
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
CN110358736B (zh) * 2016-05-20 2023-07-07 杭州朔溪生物医药有限公司 一种修饰的k562细胞、其制备方法及nk细胞培养组合物
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
CN111304255B (zh) * 2020-02-21 2023-06-09 中邦干细胞科技有限公司 一种滋养细胞、其制备方法及其在高效扩增nk细胞中的应用

Also Published As

Publication number Publication date
TW202309269A (zh) 2023-03-01
WO2022229884A2 (en) 2022-11-03
CN117203328A (zh) 2023-12-08
EP4330377A2 (en) 2024-03-06
WO2022229884A3 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
JP2021502414A5 (es)
CL2021001143A1 (es) Anticuerpos biespecificos y su uso.
CY1112668T1 (el) Εμβολιο εναντι ογκων που προκυπτει απο φυσιολογικα χημικως τροποποιημενα cd4+ κυτταρα
BR112019008560A2 (pt) célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação
AR111207A1 (es) Anticuerpos anti-lag3
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
DE602005015990D1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
ES2672895T3 (es) Generación de células T específicas de antígeno
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
BR112013012555B8 (pt) Peptídeo imunogênico isolado derivado de uma proteína antigênica, seus usos, método para a preparação de um peptídeo com capacidade de provocar a ativação de células nkt e método in vitro para obtenção de uma população de células nkt cd4+ antígeno específicas
ES2337399T3 (es) Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
CY1113247T1 (el) Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου
AR087380A1 (es) Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
AR125461A1 (es) Células presentadoras de antígeno recombinante
CU23632A1 (es) Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
MX2021006393A (es) Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
AR068984A1 (es) Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
CN105007930B (zh) 用于治疗疾病的同种异体自噬体富集组合物
CO2021018066A2 (es) Terapia con linfocitos de infiltración tumoral y sus usos
ES2306771T3 (es) Un metodo de terapia celular para tratamiento de tumores.
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.